These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37213801)

  • 1. Italian Association of Hospital Cardiologists practical guidance for sodium-glucose cotransporter 2 inhibitors use in patients with heart failure.
    Di Fusco SA; Spinelli A; Aquilani S; Borrelli N; Iannopollo G; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
    Eur Heart J Suppl; 2023 May; 25(Suppl D):D287-D293. PubMed ID: 37213801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [ANMCO practical guide for sodium-glucose cotransporter 2 inhibitor use in patients with heart failure].
    Di Fusco SA; Spinelli A; Aquilani S; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
    G Ital Cardiol (Rome); 2023 Jan; 24(1):66-74. PubMed ID: 36573513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation.
    Di Fusco SA; Gronda E; Mocini E; Lucà F; Bisceglia I; De Luca L; Caldarola P; Cipriani M; Corda M; De Nardo A; Francese GM; Napoletano C; Navazio A; Riccio C; Roncon L; Tizzani E; Nardi F; Urbinati S; Valente S; Gulizia MM; Gabrielli D; Oliva F; Imperoli G; Colivicchi F
    Eur Heart J Suppl; 2022 May; 24(Suppl C):C272-C277. PubMed ID: 35602255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.
    Escobar C; Luis-Bonilla J; Crespo-Leiro MG; Esteban-Fernández A; Farré N; Garcia A; Nuñez J
    Expert Opin Pharmacother; 2022 Oct; 23(14):1589-1599. PubMed ID: 35995759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis.
    Liu T; Li R; Wang X; Gao X; Zhang X
    Med Clin (Barc); 2022 Jul; 159(2):65-72. PubMed ID: 34872768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ability of modern therapy to improve the prognosis of patients with HF: role of angiotensin neprilysin inhibitors and sodium-glucose cotransporter inhibitors.
    Mareev YV; Mareev VY
    Kardiologiia; 2021 Jul; 61(6):4-10. PubMed ID: 34311683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.
    Tomasoni D; Fonarow GC; Adamo M; Anker SD; Butler J; Coats AJS; Filippatos G; Greene SJ; McDonagh TA; Ponikowski P; Rosano G; Seferovic P; Vaduganathan M; Voors AA; Metra M
    Eur J Heart Fail; 2022 Mar; 24(3):431-441. PubMed ID: 34894038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
    Ojha U; Reyes L; Eyenga F; Oumbe D; Watkowska J; Saint-Jacques H
    Am J Cardiovasc Drugs; 2022 Jan; 22(1):35-46. PubMed ID: 34189716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Zhou H; Peng W; Li F; Wang Y; Wang B; Ding Y; Lin Q; Zhao Y; Pan G; Wang X
    Front Cardiovasc Med; 2022; 9():875327. PubMed ID: 35600478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects.
    Kubota Y; Shimizu W
    JACC Asia; 2022 Jun; 2(3):287-293. PubMed ID: 36338417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review.
    Gitto M; Vrachatis DA; Condorelli G; Papathanasiou K; Reimers B; Deftereos S; Stefanini GG
    Cardiovasc Hematol Agents Med Chem; 2022; 20(2):90-102. PubMed ID: 34370645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
    Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL
    Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
    Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
    ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure.
    Kimura G
    Circ J; 2016 Oct; 80(11):2277-2281. PubMed ID: 27599528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists.
    Vardeny O; Vaduganathan M
    JACC Heart Fail; 2019 Feb; 7(2):169-172. PubMed ID: 30704605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
    O'Meara E; Verma S
    Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.